DB-67 is a novel, third-generation camptothecin analogue that has demonstrated high potency in preclinical studies and improved pharmacokinetic properties in humans as compared with first and second-generation products. Arno believes that this unique profile and the potential for oral administration may translate into superior efficacy and patient convenience in the treatment of brain, lung, and other cancers. We believe these advantages could allow DB-67 to become a leading product in the $1.1 billion camptothecin market.

Arno is currently conducting a single agent, ascending dose, Phase I clinical study of DB-67 in patients with advanced solid tumors. The study is evaluating the safety of DB-67, establishing the maximum tolerated dose, and characterizing the plasma PK profile.




Publications

• Chen AY, Shih SJ, Garriques LN et al., Silatecan DB-67 is a novel DNA topoisomerase I-targeted radiation sensitizer. Molecular Cancer Therapeutics 2005;4(2). February 2005.
• Bence AK, Mattingly CA, Burke TG and Adams VR, The effect of DB-67, a lipophilic camptothecin derivative, on topoisomerase I levels in non-small-cell lung cancer cells. Cancer Chemother Pharmacol (2004) 54: 354-360.
• Lopez Barcons LA, Zhang J, Siriwitayawan G et al., The Novel Highly Lipophilic Topoisomerase I Inhibitor DB-67 Is Effective in the Treatment of Liver Metastases of Murine CT-26 Colon Carcinoma. Neoplasia, Vol. 6, No. 5, September/October 2004, pp. 457-467.
• Bom D, Curran DP, Zhang J, Zimmer SG et al., The highly lipophilic DNA topoisomerase I inhibitor DB-67 displays elevated lactone levels in human blood and potent anticancer activity etc. Journal of Controlled Release 74 (2001) 325-333.
• Pollack IF, Erff M, Bom D, Burke TG et al., Potent Topoisomerase I Inhibition by Novel Silatecans Eliminates Glioma Proliferation in Vitro and in Vivo. Cancer Research 59, 4898-4905, October 1, 1999.